Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03725098 · ClinicalTrials.gov registry record · NA

Clinical Study Evaluating the Performance of HEMOBLAST Bellows Compared to FLOSEAL Hemostatic Matrix in Cardiothoracic Operations

A NA study of Cardiothoracic Surgery, sponsored by Biom'Up France SAS.

Completed
Registry status
NA
Development phase
105
Enrollment target
4
Study locations

NCT03725098 is a NA study of Cardiothoracic Surgery that has completed, run by Biom'Up France SAS. The registered enrollment target is 105 participants. The trial reports 4 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03725098, a NA study of Cardiothoracic Surgery, has completed, sponsored by Biom'Up France SAS.

COMPLETED
Registry status
NA
Development phase
105 participants
Enrollment target
4
Study locations

Study Summary

The purpose of this study is to evaluate the performance of HEMOBLAST™ compared to FLOSEAL in cardiothoracic operations.

Conditions Studied

Interventions

  • DEVICE HEMOBLAST Bellows
  • DEVICE FLOSEAL

Study Locations (4)

California

  • University of California Los Angeles - Los Angeles

Hawaii

  • Kaiser Permanente Moanalua Medical Center - Honolulu

Louisiana

  • Ochsner Clinic Foundation - New Orleans

Texas

  • Houston Methodist - Houston

Trial Details

FieldValue
Enrollment Target 105 participants
Start Date 2019-03-01
Est. Completion 2019-06-28
Phase NA

Sponsor

Biom'Up France SAS

3 total trials

What the Registry Record Tells You About NCT03725098

The ClinicalTrials.gov registry entry for NCT03725098 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biom'Up France SAS, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cardiothoracic Surgery appearing as the primary indexed condition, and to 2 interventions - of which HEMOBLAST Bellows is the first listed.

NCT03725098 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Hawaii, Louisiana.

Frequently Asked Questions

What is clinical trial NCT03725098 about?

NCT03725098 is a clinical study titled "Clinical Study Evaluating the Performance of HEMOBLAST Bellows Compared to FLOSEAL Hemostatic Matrix in Cardiothoracic Operations". The purpose of this study is to evaluate the performance of HEMOBLAST™ compared to FLOSEAL in cardiothoracic operations.

What is the current status of trial NCT03725098?

This trial is currently completed. It is a NA study. The enrollment target is 105 participants. The study started on 2019-03-01. Estimated completion is 2019-06-28.

What conditions does trial NCT03725098 study?

This clinical trial studies the following conditions: Cardiothoracic Surgery.

What interventions are being tested in trial NCT03725098?

The interventions under investigation include: HEMOBLAST Bellows (DEVICE), FLOSEAL (DEVICE).

Who is sponsoring clinical trial NCT03725098?

This trial is sponsored by Biom'Up France SAS, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03725098 being conducted?

This trial has 4 study locations across California, Hawaii, Louisiana, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.